Research programme: immunotherapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Drug Profile

Research programme: immunotherapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Alternative Names: Immuno-oncology therapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Immune-Onc Therapeutics; University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Immunological disorders

Most Recent Events

  • 18 Apr 2017 Immune-Onc Therapeutics enters into an exclusive license and collaboration agreement with University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center to develop biotherapeutics for Cancer and other Immunological disorders
  • 06 Apr 2017 Early research in Cancer in USA (Parenteral)
  • 06 Apr 2017 Early research in Immunological disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top